Rezolute, Inc. (RZLT)
| Market Cap | 166.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -77.18M |
| Shares Out | 92.73M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,289,125 |
| Open | 1.460 |
| Previous Close | 1.400 |
| Day's Range | 1.450 - 1.850 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 12.33 (+585.0%) |
| Earnings Date | Nov 6, 2025 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 585.00% from the latest price.
News
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Boston, Massachusetts--(Newsfile Corp. - December 12, 2025) - Block & Leviton is investigating Rezolute, Inc. (NASDAQ: RZLT) for potential securities law violations. Investors who have lost money in t...
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
RZLT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Dec. 12, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares c...
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed ...
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
LOS ANGELES--(BUSINESS WIRE)--Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT.
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Rezolute, Inc. (Nasdaq: RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. ...
Rezolute's rare disease drug fails main goal in late-stage trial
Rezolute said on Thursday its experimental drug for a rare condition that causes dangerously low blood sugar failed to meet the main goal in a late-stage study.
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host c...
Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move
Rezolute is positioned for upside with key catalysts ahead, notably the imminent sunRIZE Phase 3 topline readout for Ersodetug. RZLT maintains a solid $152.2M cash position, supporting a ~23-month run...
Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript
Rezolute, Inc. ( RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism November 10, 2025 12:00 PM EST Company Participants Christen Baglaneas Nevan Elam - Founder,...
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyper...
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperi...
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperi...
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperi...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyper...
Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug
Rezolute is advancing ersodetug in two phase 3 trials for hyperinsulinism: sunRIZE for congenital HI and upLIFT for tumor HI, respectively. RZLT secured FDA alignment for the upLIFT pivotal trial, all...
Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Rezolute, Inc. (NASDAQ:RZLT) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nevan Elam - Founder, CEO, Principal Financial Officer & Actin...
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif....
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch str...
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperi...
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperi...
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE N...
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD C...
Rezolute: RZ402 Could Be A Surprise Candidate In The Making
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 stud...